European Cardiology Review最新文献_第9页

IF 3

European Cardiology Review Pub Date : 2020-11-13 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.04

Philippe Amubuomombe Poli, Elkanah Omenge Orang'o, Ann Mwangi, Felix Ayub Barasa

{"title":"Factors Related to Maternal Adverse Outcomes in Pregnant Women with Cardiac Disease in Low-resource Settings.","authors":"Philippe Amubuomombe Poli, Elkanah Omenge Orang'o, Ann Mwangi, Felix Ayub Barasa","doi":"10.15420/ecr.2020.04","DOIUrl":"https://doi.org/10.15420/ecr.2020.04","url":null,"abstract":"Background: Cardiac disease is an important life-threatening complication during pregnancy. It is frequently seen in pregnant women living in resource-limited areas and often results in premature death. Aim: The aim of this hospital-based longitudinal study was to identify factors related to adverse maternal and neonatal outcomes in pregnant women with cardiac disease in low-resource settings. Methods: The study enrolled 91 pregnant women with congenital or acquired cardiac disease over a period of 2 years in Kenya. Results: Maternal and early neonatal deaths occurred in 12.2% and 12.6% of cases, respectively. The risk of adverse outcomes was significantly increased in those with pulmonary oedema (OR 11, 95% CI [2.3.52]; p=0.002) and arrhythmias (OR 16.9, 95% CI [2.5.113]; p=0.004). Limited access to care was significantly associated with adverse maternal outcomes (p≤0.001). Conclusion: Many factors contribute to adverse maternal and neonatal outcomes in pregnant women with cardiac disease. Access to comprehensive specialised care may help reduce cardiac-related complications during pregnancy.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"15 ","pages":"e68"},"PeriodicalIF":3.0,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/38/c6/ecr-15-e68.PMC7709001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38710284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Coronavirus Disease 2019 and Cardiac Arrhythmias. Coronavirus Disease 2019 and Cardiac Arrhythmias.

IF 3.2

European Cardiology Review Pub Date : 2020-11-09 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.23

Antoni Martínez-Rubio, Soledad Ascoeta, Fadwa Taibi, Josep Guindo Soldevila

引用次数: 0

The EXCEL Trial: The Surgeons' Perspective. EXCEL 试验：外科医生的视角。

IF 3.2

European Cardiology Review Pub Date : 2020-11-09 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.34

Marjan Jahangiri, Krishna Mani, Martin T Yates, Justin Nowell

引用次数: 0

What is the Real Message of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial for Academic and Practising Cardiologists? 对学术和执业心脏病专家来说，医学和侵入性方法(缺血)试验比较健康效果的国际研究的真正信息是什么?

IF 3

European Cardiology Review Pub Date : 2020-09-29 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.26

Kreton Mavromatis, William E Boden

{"title":"What is the Real Message of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial for Academic and Practising Cardiologists?","authors":"Kreton Mavromatis, William E Boden","doi":"10.15420/ecr.2020.26","DOIUrl":"https://doi.org/10.15420/ecr.2020.26","url":null,"abstract":"Defining the best management strategies for patients with stable ischaemic heart disease (SIHD) has been the subject of scientific study for nearly 50 years since the advent of coronary artery bypass grafting (CABG) surgery by Favaloro in 1967 and, a decade later, the development of percutaneous coronary intervention (PCI) by Gruentzig in 1977. Randomised controlled trials of CABG surgery versus medical therapy were initiated in the late 1970s and 1980s in patients with SIHD and showed that revascularisation reduced MI and mortality in subsets of patients with three-vessel and left main coronary artery disease (CAD). In the 1990s, randomised controlled trials of PCI versus medical therapy, initially with balloon angioplasty (Angioplasty Compared to Medicine [ACME] and Second Randomised Intervention Treatment of Angina [RITA-2]), were similarly undertaken in SIHD patients and showed significantly better angina relief and treadmill exercise performance with PCI, although no reduction in death or MI. Nevertheless, the widespread availability of PCI greatly expanded the number of patients who could be revascularised safely and pushed revascularisation therapy to become routine for SIHD patients in many locales.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"15 ","pages":"e64"},"PeriodicalIF":3.0,"publicationDate":"2020-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/e3/ecr-15-e64.PMC7539144.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38475985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk. 阻塞性睡眠呼吸暂停综合征：持续气道正压疗法预防心血管风险。

IF 3.2

European Cardiology Review Pub Date : 2020-09-29 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.10

María Pilar Resano-Barrio, Ramón Arroyo-Espliguero, María Carmen Viana-Llamas, Olga Mediano

{"title":"Obstructive Sleep Apnoea Syndrome: Continuous Positive Airway Pressure Therapy for Prevention of Cardiovascular Risk.","authors":"María Pilar Resano-Barrio, Ramón Arroyo-Espliguero, María Carmen Viana-Llamas, Olga Mediano","doi":"10.15420/ecr.2020.10","DOIUrl":"10.15420/ecr.2020.10","url":null,"abstract":"Obstructive sleep apnoea (OSA) syndrome is characterised by the presence of apnoea or obstructive hypopnoea during sleep, accompanied by hypoxia. It is estimated that the syndrome affects approximately 10% of men and 15% of women. Diagnosis and treatment rates have increased in recent years, but the condition remains undiagnosed in a high percentage of patients. Recent evidence suggests that OSA may increase the risk of cardiovascular disease. The relationship between OSA and cardiovascular disease can be explained, at least in part, by the coexistence of cardiovascular risk factors in the two pathologies, such as age, overweight, smoking and sedentary lifestyle. However, OSA has been independently associated with the risk of developing hypertension, cerebrovascular disease, ischaemic heart disease, heart failure and arrhythmias. Clinical trials that have evaluated the efficacy of continuous positive airway pressure (CPAP) treatment in primary and secondary cardiovascular prevention have not demonstrated a significant reduction in the incidence or recurrence of cardiovascular events. This article analyses the relationship between OSA and cardiovascular risk and discusses recent clinical trials on the efficacy of CPAP in primary and secondary cardiovascular prevention.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"15 ","pages":"e65"},"PeriodicalIF":3.2,"publicationDate":"2020-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/c9/ecr-15-e65.PMC7539148.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38480832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is the Real Message of the ISCHEMIA Trial from a Clinician's Perspective? 从临床医生的角度看，缺血试验的真正意义是什么?

IF 3

European Cardiology Review Pub Date : 2020-08-31 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.27

Islam Y Elgendy, Carl J Pepine

引用次数: 0

The Role of Nocturnal Blood Pressure and Sleep Quality in Hypertension Management. 夜间血压和睡眠质量在高血压治疗中的作用。

IF 3

European Cardiology Review Pub Date : 2020-08-24 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.13

Francesco P Cappuccio

{"title":"The Role of Nocturnal Blood Pressure and Sleep Quality in Hypertension Management.","authors":"Francesco P Cappuccio","doi":"10.15420/ecr.2020.13","DOIUrl":"https://doi.org/10.15420/ecr.2020.13","url":null,"abstract":"The accurate measurement, prediction and treatment of high blood pressure (BP) are essential to the management of hypertension and the prevention of its associated cardiovascular (CV) risks. However, even if BP is optimally controlled during the day, nocturnal high blood pressure may still increase the risk of CV events. The pattern of circadian rhythm of BP can be evaluated by ambulatory BP monitoring (ABPM). Night-time ABPM is more closely associated with fatal and nonfatal CV events than daytime ambulatory BP. However, the use of ABPM is limited by low availability and the fact that it can cause sleep disturbance, therefore may not provide realistic nocturnal measurements. Home blood pressure monitoring (HBPM) offers an inexpensive alternative to ABPM, is preferred by patients and provides a more realistic assessment of BP during an individual's daily life. However, until recently, HBPM did not offer the possibility to measure nocturnal (sleep time) BP. The development and validation of new BP devices, such as the NightView (OMRON Healthcare, HEM9601T-E3) HBPM device, could overcome these limitations, offering the possibility of daytime and night-time BP measurements with minimal sleep disturbance.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"15 ","pages":"e60"},"PeriodicalIF":3.0,"publicationDate":"2020-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/5f/ecr-15-e60.PMC7479543.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38391651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

The Impact of Ethnicity on Cardiac Adaptation. 种族对心脏适应的影响。

IF 3

European Cardiology Review Pub Date : 2020-08-24 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.01

Uchenna Ozo, Sanjay Sharma

引用次数: 12

The Coronavirus Disease 2019 Outbreak Highlights the Importance of Sex-sensitive Medicine. 2019冠状病毒病的爆发凸显了性别敏感医学的重要性。

IF 3

European Cardiology Review Pub Date : 2020-08-24 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.28

Angela Hem Maas, Sabine Oertelt-Prigione

引用次数: 3

Treatment of Coronavirus Disease 2019: Shooting in the Dark. 2019冠状病毒病的治疗:在黑暗中射击。

IF 3

European Cardiology Review Pub Date : 2020-08-10 eCollection Date: 2020-02-01 DOI: 10.15420/ecr.2020.21

Juan Tamargo

{"title":"Treatment of Coronavirus Disease 2019: Shooting in the Dark.","authors":"Juan Tamargo","doi":"10.15420/ecr.2020.21","DOIUrl":"https://doi.org/10.15420/ecr.2020.21","url":null,"abstract":"The identification of effective interventions against the coronavirus disease 2019 (COVID-19) pandemic has become a health priority. The rational treatment of a disease is based on the knowledge of its pathophysiology, the identification of a therapeutic target and the confirmation of the efficacy and safety of the selected therapeutic intervention in randomised controlled trials. However, we are facing the COVID-19 pandemic without a clear understanding of the pathophysiology of the disease. As we are fighting against a viral infection, drugs previously developed or approved to treat other viral infections or that exhibit a broad-spectrum antiviral activity, anti-inflammatory drugs and drugs against cytokine storm are currently being tested. Unfortunately, the efficacy and safety of these medications remain uncertain, and some may increase the risk of cardiovascular complications in patients with COVID-19. Thus, at the present time, due to the lack of solid scientific data to support a therapeutic strategy, we truly are shooting in the dark with the treatment of COVID-19. We must wait for the results of ongoing randomised, controlled studies before the widespread adoption of these drugs. In the meantime, investigational anti-COVID-19 drugs should be used in hospitals or as part of clinical trials.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"15 ","pages":"e59"},"PeriodicalIF":3.0,"publicationDate":"2020-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/eb/ecr-15-e59.PMC7479539.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38391650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2